That old adage ‘Fool me once shame on you, fool me twice shame on me’ looks like a perfect description of why the heart disease establishment should be hanging its collective head. Having totally bought into one cholesterol-lowering class of drug – statins – it now looks ready to open its arms and pockets equally wide to embrace a new improved more powerful son of statin drug – the PCSK9 inhibitors – that will drive that deadly fatty stuff right to the floor.

We are being doctored to death. GPs’ surgeries and public health bodies routinely warn of hazards lurking all around us. They tell us sunshine is bad. Drinking alcohol is bad. Cholesterol is bad. Saturated fat is bad. Being overweight is bad.

Last month two new cholesterol lowering drugs stepped into the limelight at AHA’s (American Heart Association) annual conference. Neither is likely to make it to market until the end of next year but soon after that they are likely to be coming to a doctor’s surgery near you.

Rarely have I been proven wrong quite so fast. After confidently informing the world that the post-statin cholesterol lowering drugs PCSK9 inhibitors would be launched upon an unsuspecting public in the near future, with billion dollar marketing budgets, it seems that I was wrong. Although who knows, I may be wrong about being wrong. (Read more…)

An era is coming to an end. Statins, the world’s most widely prescribed and profitable drugs, have, with the exception Crestor (rosuvastatin), all come off patent and their price has plummeted. Good news for NHS accountants not so good for company profits. (Read more…)

Dr Kendrick has been warning about the almost total lack of effectiveness of statin drugs for over a decade during which time the number of prescriptions written for these drugs in England alone has more than doubled from from 25 million to over 50 million. (read more…)